Mineralys Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
150 N. RADNOR CHESTER RD., RADNOR, PA, 19087
Mailing Address
150 N. RADNOR CHESTER RD., RADNOR, PA, 19087
Phone
(888) 378-6240
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$646.69M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 3 Initial insider ownership report | March 4, 2026 | View on SEC |
Annual Reports
10-K
March 12, 2026
- Submitted New Drug Application (NDA) for lorundrostat to the FDA in December 2025.
- FDA accepted NDA for review with a Prescription Drug User Fee Act (PDUFA) target action date in September 2026.
Insider Trading
STRONG SELL
5 insiders
30 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.